Warning: The NCBI web site requires JavaScript to function. more...
Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males.
Findlay D, Chehade M, Tsangari H, Neale S, Hay S, Hopwood B, Pannach S, O'Loughlin P, Fazzalari N.
Arthritis Res Ther. 2008;10(1):R2. Epub 2008 Jan 8.
Related citations
The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis.
Fazzalari NL, Kuliwaba JS, Atkins GJ, Forwood MR, Findlay DM.
J Bone Miner Res. 2001 Jun;16(6):1015-27.
sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.
Doumouchtsis KK, Kostakis AI, Doumouchtsis SK, Tziamalis MP, Tsigris C, Kostaki MA, Perrea DN.
J Endocrinol Invest. 2007 Oct;30(9):762-6.
[Osteoprotegerin mRNA/receptor activator of NF-kappaB ligand mRNA expressions in bone tissues of glucocorticoid-induced osteonecrosis of the femoral head].
Wang J, Wang K, Shi Z, Zhang M.
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2008 Oct;22(10):1161-4. Chinese.
Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
Doumouchtsis K, Perrea D, Doumouchtsis S, Tziamalis M, Poulakou M, Vlachos I, Kostakis A.
Ther Apher Dial. 2009 Feb;13(1):49-55.
Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
Shaarawy M, Fathy SA, Mehany NL, Hindy OW.
Clin Chem Lab Med. 2007;45(11):1498-503.
Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck.
Tsangari H, Findlay DM, Kuliwaba JS, Atkins GJ, Fazzalari NL.
Bone. 2004 Jul;35(1):334-42.
[Osteoprotegerin and receptor activator of nuclear factor kappa B ligand mRNAs expression in BMSCs of glucocorticoid-induced necrosis of the femoral head patients].
Wang J, Gao H, Wang K, Li W, Shi Z, Zhang M.
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2009 Jul;23(7):777-80. Chinese.
Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
Giusti M, Cecoli F, Fazzuoli L, De Franchis V, Ceresola E, Ferone D, Mussap M, Minuto F.
Metabolism. 2007 May;56(5):699-707.
Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
Reyes-García R, Muñoz-Torres M, García DF, Mezquita-Raya P, García Salcedo JA, de Dios Luna J.
Menopause. 2010 Jan-Feb;17(1):140-4.
The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levels.
Martini G, Gennari L, De Paola V, Pilli T, Salvadori S, Merlotti D, Valleggi F, Campagna S, Franci B, Avanzati A, Nuti R, Pacini F.
Thyroid. 2008 Apr;18(4):455-60.
Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75.
Liu JM, Zhao HY, Ning G, Zhao YJ, Chen Y, Zhang Zh, Sun LH, Xu MY, Chen JL.
Calcif Tissue Int. 2005 Jan;76(1):1-6. Epub 2004 Oct 7.
The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study.
Stern A, Laughlin GA, Bergstrom J, Barrett-Connor E.
Eur J Endocrinol. 2007 May;156(5):555-62.
Circulating osteoprotegerin and soluble RANK ligand in systemic sclerosis.
Dovio A, Data V, Carignola R, Calzolari G, Vitetta R, Ventura M, Saba L, Severino A, Angeli A.
J Rheumatol. 2008 Nov;35(11):2206-13. Epub 2008 Oct 1.
Relationships between OPG, RANKL, bone metabolism, and bone mineral density in biliary atresia.
Honsawek S, Chaiwatanarat T, Vejchapipat P, Chongsrisawat V, Thawornsuk N, Poovorawan Y.
Pediatr Surg Int. 2009 Mar;25(3):261-7. Epub 2009 Jan 29.
Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
Nabipour I, Larijani B, Vahdat K, Assadi M, Jafari SM, Ahmadi E, Movahed A, Moradhaseli F, Sanjdideh Z, Obeidi N, Amiri Z.
Menopause. 2009 Sep-Oct;16(5):950-5.
Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patients with beta-thalassemia major.
Angelopoulos NG, Goula A, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, Malaktari S, Athanasiou V, Tolis G.
J Bone Miner Metab. 2007;25(1):60-7. Epub 2007 Jan 1.
The HLA-B27 transgenic rat, a model of spondyloarthritis, has decreased bone mineral density and increased RANKL to osteoprotegerin mRNA ratio.
Rauner M, Stupphann D, Haas M, Fert I, Glatigny S, Sipos W, Breban M, Pietschmann P.
J Rheumatol. 2009 Jan;36(1):120-6.
Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
Mountzios G, Dimopoulos MA, Bamias A, Papadopoulos G, Kastritis E, Syrigos K, Pavlakis G, Terpos E.
Acta Oncol. 2007;46(2):221-9.
Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism.
Baek KH, Oh KW, Lee WY, Tae HJ, Rhee EJ, Han JH, Cha BY, Kim YJ, Lee KW, Son HY, Kang SK, Kim CC, Kang MI.
Bone. 2006 Dec;39(6):1352-60. Epub 2006 Aug 14.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on